By DoM Communications | Date published: August 15, 2025
Shyam Patel Studies Early Identification of TP53 Mutations and TP53 Allelic State in Myelodysplastic Neoplasms and Acute Myeloid Leukemia
TP53-mutant MDS and AML are the highest risk myeloid neoplasms, and many clinical trials have not met primary endpoints, leaving this an area of unmet clinical need. In a recent study published in the journal Cancer, Shyam Patel, MD, PhD, associate professor of medicine in the Division of Hematology/Oncology, and his colleagues from Hematopathology performed immunohistochemistry for the p53 protein to help with early and rapid identification of TP53 mutation. They systematically analyzed 145 bone marrow specimens from 82 unique patients with TP53-mutant MDS or AML. They found that the specificity and positive predictive values were high, suggesting that p53 immunohistochemistry is a valuable rule-in test. This immunohistochemical test may serve as an early biomarker for the mutation, has a rapid turnaround time, and is cost-efficient.